<DOC>
	<DOC>NCT01932528</DOC>
	<brief_summary>To evaluate the metabolism and routes and extent of elimination of telotristat etiprate and its primary metabolite LX1033.</brief_summary>
	<brief_title>An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males</brief_title>
	<detailed_description />
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Serotonin Syndrome</mesh_term>
	<criteria>Healthy male subjects aged 30 to 65 years of age. Male subjects and their partners must agree to use an adequate method of contraception Historically able to produce a minimum of 1 bowel movement every day on most days Female subjects Use of any medication or supplement within 5 days prior to Dosing Radiation exposure exceeding 5 millisieverts (mSv) in the last 12 months or 10 mSv in the last 5 years Current smokers or the use of cigarettes within 90 days prior to Screening History or renal disease or abnormal kidney function History of hepatic disease Acute diarrhea or constipation within 7 days of dosing Positive urine glucose at Screening</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Absorption</keyword>
	<keyword>Metabolism</keyword>
	<keyword>Excretion</keyword>
</DOC>